RemeGen 2025 ESG Report: Energy Intensity Cut by 49%, R&D Investment Reaches RMB1.22 Billion

Bulletin Express04-28

RemeGen released its sixth Environmental, Social and Governance Report covering January–December 2025, detailing substantial progress across climate action, product quality, and human capital management.

Key operational metrics show a notable improvement in resource efficiency. Energy consumption per RMB10,000 of output fell to 54.71 kgce, a 49 percent decrease versus 2024, surpassing the firm’s 2 percent reduction target. Water intensity dropped 53.8 percent to 0.24 tonnes per unit of product, also well ahead of plan. Total greenhouse-gas emissions were 50,511.54 tCO₂e, with emission intensity at 0.16 tCO₂e per RMB10,000 of revenue—marking a third consecutive annual decline.

RemeGen sustained a perfect safety record: zero fire, special-equipment, fatal or serious injury incidents, and no new occupational disease cases. Occupational health and safety spending totaled RMB0.59 million, while all supplier safety training achieved 100 percent coverage.

Product stewardship remained strong. The company recorded no product recalls, passed ISO 9001 recertification, and held 13 quality-focused training sessions alongside more than 2,440 quality-system document trainings. Intellectual-property protection was reinforced with 96 new invention-patent applications and 29 grants; 22 IP training sessions drew 330 participants.

Innovation funding stayed robust: total R&D expenditure reached RMB1.22 billion, and R&D staff accounted for 26.65 percent of the workforce. Major pipeline milestones included Chinese market approval for telitacicept in generalized myasthenia gravis, a BLA submission for IgA nephropathy, and global phase III progress for several oncology and ophthalmology candidates.

Governance enhancements included 15 board-level ESG meetings, full coverage of business-ethics training for directors, and zero material bribery or corruption cases. The firm’s ESG working group now reports regularly to the board, and climate-related risks and opportunities are integrated into corporate strategy.

Human-capital initiatives featured 100 percent coverage of social insurance, non-salary benefits, and training. Overall 3,241 employees received an average 10.4 training hours; women comprised 55 percent of the workforce. Employee-care spending totaled RMB16.09 million, and public-welfare contributions reached RMB12.52 million, including disease-education programs and rural-revitalization support.

Operationally, RemeGen secured “National Green Factory” and “Shandong Provincial Green Factory” status, completed ISO 45001 surveillance and progressed ISO 50001 certification. Waste-water intensity fell, while hazardous and non-hazardous waste generation totaled 30.88 tonnes and 92.19 tonnes respectively.

The company’s 2020–2030 climate goal targets a 50 percent reduction in emission intensity versus the 2020 baseline, with an interim objective of 0.4 percent annual CO₂ cuts through 2030; current data indicate the trajectory remains on track.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment